



NDA 21936

NDA APPROVAL

Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Rd.
P.O. Box 368
Ridgefield, CT 06877-0368

Attention: Ingeborg Army-Cornejo, MD
Sr. Associate Director
Regulatory Affairs

Dear Dr. Army-Cornejo:

Please refer to your New Drug Application (NDA) dated November 16, 2007, received November 16, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Spiriva Respimat (tiotropium bromide) Inhalation Spray.

We acknowledge receipt of your amendments dated January 4 and 10, February 11, and 27, March 18, April 4, 11, and 18, May 7 and 21(2), June 10, 20, and 23, July 1, 10, 18, 24, 25, 28, and 29, August 5 and 13, 2008, and November 8, 2011, and February 26(2), April 11, 2013, and March 24, April 9, 11, 14, and 15, May 9, 22, and 23, June 9, 16, July 21, August 10, 12, and 21, September 11, 19, and 24, 2014.

The March 24, 2014, submission constituted a complete response to our September 16, 2008, action letter.

This new drug application provides for the use of Spiriva Respimat (tiotropium bromide) Inhalation Spray for long-term, once-daily maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema, and for reducing COPD exacerbations.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content

of labeling must be identical to the enclosed labeling (text for the Package Insert, text for Instructions for Use). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 21936.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

EXPIRATION DATING PERIOD

A 36-month expiration dating period is granted for Spiriva Respimat (tiotropium bromide) Inhalation Spray kit when stored at 25°C (77°F); excursions permitted to 15°C–30°C (59°F–86°F). A 3-months in-use expiration dating period is granted for the assembled drug product, i.e., 3 months from the date when drug product cartridge is inserted into the RESPIMAT device.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable due to the fact that the disease/condition does not occur in the pediatric population.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jessica Lee, Regulatory Project Manager, at (301) 796-3769.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, MD, PhD
Director
Division of Pulmonary, Allergy, and
Rheumatology Products
Office of Drug Evaluation II

Enclosure(s):

Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BADRUL A CHOWDHURY
09/24/2014